Xenetic Biosciences Inc (XBIO)


Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Xenetic Biosciences Inc chart...

About the Company

xenetic biosciences (nasdaq: xbio) is a clinical-stage biopharmaceutical company focused on discovery, research and development of next-generation biologic drugs and novel oncology therapeutics. xenetic's proprietary drug development platforms include polyxen™, which enables next generation biologic drugs by improving their half-life and other pharmacological properties. xenetic's lead investigational product candidates include fda orphan designated oncology therapeutic sodium cridanimod for the treatment of progesterone receptor negative endometrial cancer, and a polysialylated form of erythropoietin for the treatment of anemia in pre-dialysis patients with chronic kidney disease. xenetic is also working together with shire plc (formerly baxalta, baxter incorporated and baxter healthcare) to develop a novel series of polysialylated blood coagulation factors, including a next generation factor viii. this collaboration relies on xenetic's polyxen technology to conjugate polysialic acid

Exchange

NASDAQ

Website

https://www.xeneticbio.com/

$2M

Total Revenue

5

Employees

$11M

Market Capitalization

-2.49

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $XBIO News

Xenetic Biosciences Inc XBIO

5d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Xenetic Biosciences Inc. Wt

19d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Xenetic Biosciences, Inc. (XBIO)

5d ago, source: Yahoo Finance

*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...

Xenetic Biosciences, Inc. (XBIOW)

9mon ago, source: Yahoo Finance

Company building growing body of preclinical data to guide pathway to first in human trial for DNase-based oncology platform FRAMINGHAM, MA / ACCESSWIRE / January 17, 2024 /Xenetic Biosciences, Inc.

Xenetic Biosciences, Inc. (XBIO)

1y ago, source: Yahoo Finance

Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...

Xenetic Biosciences, Inc. Common Stock (XBIO)

9y ago, source: Nasdaq

*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past ...

Xenetic Biosciences Inc.

19d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Xenetic Biosciences Inc (XBIO)

20d ago, source: Investing

Investing.com – U.S. equities were lower at the close on Wednesday, as losses in the Industrials, Oil & Gas and Basic Materials sectors propelled shares lower. At the close in... Investing.com – U.S.

Xenetic Biosciences, Inc. (XBIO)

2mon ago, source: Yahoo Finance

Company building growing body of preclinical data to guide pathway to first in human trial for DNase-based oncology platform FRAMINGHAM, MA / ACCESSWIRE / January 17, 2024 /Xenetic Biosciences, Inc.

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...